The 4 Wall Street analysts covering Apnimed, Inc. hold a median 12-month price target of $50 — +204.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Apnimed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (48): Smaller than most of the companies we track.
Issuance (2): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on APMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +204.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Aug 2026 | B of A Securities | Initiates | Buy | $41 |
| 25 Aug 2026 | Cantor Fitzgerald | Initiates | Overweight | $60 |
| 25 Aug 2026 | Evercore ISI Group | Initiates | Outperform | — |
| 25 Aug 2026 | LifeSci Capital | Initiates | Outperform | $50 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
APMD appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 69% of US stocks
Cheaper than 19% of US stocks
Cheaper than 96% of US stocks
Cheaper than 11% of US stocks
Higher than 9% of US stocks
Higher than 96% of US stocks
Higher than 14% of US stocks
Higher than 99% of US stocks
Higher than 44% of US stocks
Higher than 39% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Apnimed, Inc. has a market value of $682.7M and an enterprise value of $846.3M.
Revenue in the twelve months to 30 June 2026: $117.1M. The latest quarter shrank 29.4% year on year.
Net income over the same four quarters: $98.2M, a 83.8% net margin.
Diluted earnings per share, trailing twelve months: $1.87.
Free cash flow in the twelve months to 30 June 2026: −$84.1M.
Trailing P/E: 2.3×; forward P/E: −4.1× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Apnimed, Inc. employs 81 people — $1.4M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Apnimed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Apnimed will present five abstracts, including two late-breakers, at CHEST 2026. A CHEST-led panel will feature data from the Phase 3 SynAIRgy and LunAIRo trials, which explore potential new approaches to obstructive sleep apnea (OSA) patient management.
Why it matters — The presentations will share Phase 3 trial data relevant to Apnimed’s work in OSA management.
Apnimed, Inc. announced that on October 1, 2026, its board's compensation committee granted non-qualified stock options to purchase an aggregate of 481,300 common shares to 19 new non-executive employees under the company's 2026 Inducement Plan. Each option has an exercise price of $22.54, matching the company's closing price on the grant date, with vesting over four years subject to continued employment.
Why it matters — The inducement stock option grants signal recent hiring and potential future dilution for existing shareholders, making the vesting schedule and share count relevant for APMD watchers.
Apnimed is a late-stage company focused on AD109 (Oxnimbi) for obstructive sleep apnea, having demonstrated Phase 3 efficacy and a manageable safety profile. Its NDA is under FDA review with a February 2027 PDUFA date, and the company holds a strong cash position with a transition from R&D to pre-commercial buildout.
Why it matters — APMD watchers would care because the February 2027 PDUFA decision for AD109 represents a key regulatory catalyst, with the company's cash runway supporting launch activities.
Apnimed, Inc. announced its financial results for the second quarter ended June 30, 2026, and provided a corporate update. The company is a late-stage clinical pharmaceutical firm focused on developing oral therapies for sleep-related breathing diseases.
Why it matters — The report offers APMD watchers an update on the company's quarterly financial performance and its ongoing clinical-stage progress.
Apnimed announced that its compensation committee granted non-qualified stock options to 10 new non-executive employees on August 31, 2026, covering an aggregate of 428,428 shares of common stock under its 2026 Inducement Plan. Each option has an exercise price of $26.85 per share, equal to the company's closing price on September 1, 2026, with vesting scheduled over four years.
Why it matters — APMD watchers would care because the inducement grants signal new employee hiring and equity compensation activity, which are relevant to share count and personnel matters.
The 4 Wall Street analysts covering Apnimed, Inc. have a median 12-month price target of $50, with estimates ranging from $41 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Apnimed, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Apnimed, Inc. 1 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Apnimed, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (48 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +204.9% from the last close, and Ticker Nerd's factor model ranks Apnimed, Inc. 1 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Apnimed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for APMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $41 to $60 over the next 12 months.
Apnimed, Inc. is a clinical-stage pharmaceutical company focused on developing oral therapies for sleep-related breathing diseases, with an emphasis on obstructive sleep apnea.
The most recent item we track (GlobeNewsWire, 12 Oct 2026): "Apnimed to Present Five Abstracts, Including Two Late-Breakers at CHEST 2026". Apnimed will present five abstracts, including two late-breakers, at CHEST 2026. A CHEST-led panel will feature data from the Phase 3 SynAIRgy and LunAIRo trials, which explore potential new approaches to obstructive sleep apnea (OSA) patient management.
Apnimed, Inc. is a clinical-stage pharmaceutical company focused on developing oral therapies for sleep-related breathing diseases, with an emphasis on obstructive sleep apnea. Its lead product candidate, AD109, is an investigational once-daily oral therapy designed to target the underlying neuromuscular dysfunction associated with OSA. The company’s work centers on advancing medicines that may address mild, moderate, and severe forms of sleep apnea through a simplified pill-based approach. Based in Cambridge, Massachusetts, and founded in 2017, Apnimed operates within the biotechnology and sleep medicine markets, where it contributes to the development of new treatment options for patients with chronic breathing disorders during sleep.
CEO Mr. Kevin Robert Lind · 81 employees · United States · https://apnimed.com
